Codexis to Present at Four Investment Conferences in September
Get Alerts CDXS Hot Sheet
Join SI Premium – FREE
REDWOOD CITY, Calif., Aug. 31, 2017 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading protein engineering company, announces that management will present at four investment conferences in September:
- BioCentury 24th Annual NewsMakers in the Biotech Industry Conference on Friday, September 8, 2017 at 10:00 a.m. Eastern time (7:00 a.m. Pacific time). The conference is being held at the Millennium Broadway Hotel & Conference Center in New York City;
- Rodman & Renshaw 19th Annual Global Investment Conference on Monday, September 11, 2017 at 5:05 p.m. Eastern time (2:05 p.m. Pacific time). The conference is being held at the New York Palace Hotel in New York City;
- 2017 KeyBanc Capital Market’s Basic Materials & Packaging Conference on Wednesday, September 13, 2017 at the InterContinental Boston; and
- Janney Montgomery Scott’s Bioproduction & Biostorage Forum on Tuesday, September 19, 2017 at the Union League Club in New York City.
A live webcast and replay of the presentations at the NewsMakers and Rodman & Renshaw Conferences will be available on the Investors section of the company's website, http://ir.codexis.com/.
About Codexis, Inc.Codexis, Inc. is a leading protein engineering company that applies its technology to the development of biocatalysts for commercial manufacture of pharmaceuticals and fine chemicals, as well as the development of enzymes as biotherapeutics and for molecular diagnostics. Codexis’ proven technology enables implementation of biocatalytic solutions to meet customer needs for rapid, cost-effective and sustainable manufacturing. For more information, see www.codexis.com.
Contacts: Investors LHA Investor Relations Jody Cain (310) 691-7100 [email protected] Media SCORR Marketing Lea Studer (308) 237-5567 [email protected]Source: Codexis, Inc.
Create E-mail Alert Related Categories
Press ReleasesRelated Entities
KeyBanc, Janney Montgomery ScottSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share